Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL18498857 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL16267234 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL192603 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL508898 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL525361 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL5036694 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL9731700 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL18237169 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL1163855 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA | |
| Ethyl Acetate SCHEMBL1150646 | 1.00 | ALDH1A1 (0.93) | ALDH1A1LMNAHSD17B10TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149261-A1 | INHIBITOR OF COMPLEMENT FACTOR B | 南京正大天晴制药有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-118307564-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118159541-A | Gonadotropin releasing hormone antagonist and preparation method and application thereof | 山东绿叶制药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-20240116989-A1 | PROCESS FOR THE PREPARATION OF CYCLIC DEPSIPEPTIDES | ONKURE, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-117486876-A | Compounds as inhibitors of Akt kinase | 正大天晴药业集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20040106595-A1 | 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-06-03 | — | — | US | disclosed |
| CN-1487934-A | 2H-1-benzopyran derivatives, process for their preparation and pharmaceutical compositions containing them | ������˹ҩƷ��˾ | 2004-04-07 | — | — | CN | disclosed |
| US-20040029819-A1 | Process for the synthesis of optically active anthracyclines | MENARINI RICERCHE S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| CN-1474827-A | Process for synthesis of optically active anthracyclines | ÷�������о����ɷݹ�˾ | 2004-02-11 | — | — | CN | disclosed |
| EP-1355906-A1 | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-10-29 | — | — | EP | disclosed |
| EP-1335927-A1 | PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE ANTHRACYCLINES | Menarini Ricerche S.p.A. (IT) | 2003-08-20 | — | — | EP | disclosed |
| CN-1411444-A | Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same | SEUWIEL LAB (FR) | 2003-04-16 | — | — | CN | disclosed |
| WO-2002059113-A1 | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002040496-A1 | PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE ANTHRACYCLINES | MENARINI RICERCHE S.P.A. (IT) | 2002-05-23 | — | — | WO | disclosed |
| US-5043152-A | Radiography | GUERBET S.A. (FR) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116989-A1 | PROCESS FOR THE PREPARATION OF CYCLIC DEPSIPEPTIDES | VIP, LPXN, NGLY1 | CHRM5 2386/4885CHRM1 1472/4885CHRM3 2988/4885 |
| US-20040106595-A1 | 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof | CYP19A1, BRCA1, HPD | CHRM5 2447/4885CHRM1 1663/4885CHRM3 2062/4885 |
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | CHRM5 4868/4885CHRM1 4876/4885CHRM3 4474/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | CHRM5 4855/4885CHRM1 4669/4885CHRM3 4663/4885 |
| US-20040029819-A1 | Process for the synthesis of optically active anthracyclines | DHPS, GNPAT, CYP8B1 | CHRM5 3971/4885CHRM1 3900/4885CHRM3 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.